Malin (MLLNF) has released an update.
Malin Corporation PLC has successfully sold its entire stake in CG Oncology for approximately €28.5 million, securing a 175% return on investment. The company plans to conduct a capital return to shareholders through a tender offer in the fourth quarter of 2024, with an estimated intrinsic equity value per share of €6.60 as of July 23, 2024. Malin’s current cash balance stands at €62.4 million following the divestiture.
For further insights into MLLNF stock, check out TipRanks’ Stock Analysis page.
